Akebia Therapeutics (STU:AX9) Inventory Turnover: 0.87 (As of Mar. 2026)

What is Akebia Therapeutics Inventory Turnover?

Akebia Therapeutics STU:AX9 +1.24% 49 Inventory Turnover is 0.87 as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 49/100 and a GF Value™ of €1.11 (Fairly Valued). The stock has 5 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Akebia Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was €10.6 Mil. Akebia Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2026 was €12.3 Mil. Akebia Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.87.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Akebia Therapeutics's Days Inventory for the three months ended in Mar. 2026 was 105.46.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Akebia Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.27.

Akebia Therapeutics (STU:AX9) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Akebia Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	12.2865	/	10.631	*	365 / 4
	=	105.46

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Akebia Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	12.2865	/	46.316
	=	0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Akebia Therapeutics Inventory Turnover Related Terms

Akebia Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Inventory Turnover can be seen below:

Akebia Therapeutics Inventory Turnover Chart

Akebia Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

3.23

3.06

3.91

4.04

2.34

Akebia Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.42	0.53	0.53	0.73	0.87

49GF Score

Akebia Therapeutics Inc STU:AX9

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Akebia Therapeutics Inventory Turnover Calculation

Akebia Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	33.7	/ (	(15.512	+	13.331)	/	2 )
=	33.7	/	14.4215
=	2.34

Akebia Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	10.631	/ (	(13.331	+	11.242)	/	2 )
=	10.631	/	12.2865
=	0.87

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.87 mean?

Akebia Therapeutics (STU:AX9) has a Inventory Turnover of 0.87 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Akebia Therapeutics and its competitors.

Is Akebia Therapeutics' Inventory Turnover too high?

Akebia Therapeutics' current Inventory Turnover is 0.87. Overall, Akebia Therapeutics has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Akebia Therapeutics' Inventory Turnover compare to TKNO and ORGO?

Akebia Therapeutics' Inventory Turnover of 0.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Drug Manufacturers company?

A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Inventory Turnover is 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Akebia Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.11, compared to a current price of €1.07 — trading 4.1% below its estimated fair value. The current Inventory Turnover is 0.87. Akebia Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Inventory Turnover is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €1.07 is trading 4.1% below its estimated GF Value™ of €1.11. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

Inventory Turnover: 0.87
GF Value™: €1.11 vs. price of €1.07 (4.1% below fair value)
GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TKNO ORGO SIGA ANIK LFCR ELTP DERM EBS ASRT NIKA XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges AKBA:USA

Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142

Website https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

49GF Score

Get the complete analysis for STU:AX9

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.07

Price

€1.11

GF Value

View STU:AX9 Analysis

See Inventory Turnover data for all stocks →